Literature DB >> 30315341

Postprandial hypoglycaemia after Roux-en-Y gastric bypass in individuals with type 2 diabetes.

Daniela Guarino1,2, Diego Moriconi1, Andrea Mari3, Eleni Rebelos1, Daria Colligiani1, Simona Baldi1, Marco Anselmino4, Ele Ferrannini2, Monica Nannipieri5.   

Abstract

AIMS/HYPOTHESIS: Postprandial hypoglycaemia (PPHG) is a complication of Roux-en-Y gastric bypass (RYGB) surgery in normoglycaemic individuals. In type 2 diabetes, RYGB improves glucose metabolism, but whether this improvement is related to the later development of PPHG is not known. We investigated the presence and mechanisms of PPHG in individuals with type 2 diabetes undergoing RYGB.
METHODS: A total of 35 obese individuals with type 2 diabetes underwent an OGTT before and 24 months after surgery. PPHG was defined as a plasma glucose level of ≤3.3 mmol/l when not taking glucose-lowering agents. Insulin sensitivity was assessed by oral glucose insulin sensitivity index and beta-cell function by mathematical modelling of the plasma glucose, insulin and C-peptide concentrations.
RESULTS: After surgery, PPHG occurred in 11 of 35 individuals who underwent RYGB. Before surgery, BMI was lower, glycaemic control less good and time of glucose peak earlier in the PPHG vs No PPHG group, and the duration of diabetes was shorter with PPHG (all p ≤ 0.05). In addition, insulin sensitivity was greater in the PPHG than No PPHG group (p = 0.03). After surgery, BMI and fasting glucose and insulin levels decreased similarly in the two groups; insulin secretion during the first hour of the OGTT increased more in the PPHG than No PPHG group (p = 0.04). Beta-cell glucose sensitivity increased more in individuals with PPHG than those without (p = 0.002). Over the same time interval, the glucagon-like peptide 1 (GLP-1) response was lower in individuals with PPHG before surgery (p = 0.05), and increased more after surgery. At 2 h after glucose ingestion in the OGTT, postsurgery plasma glucagon level was significantly lower in the PPHG than No PPHG group. CONCLUSIONS/
INTERPRETATION: In morbidly obese individuals with type 2 diabetes, spontaneous PPHG may occur after bariatric surgery independently of a remission of diabetes. Before surgery, individuals had a shorter duration and were more insulin sensitive. Two years after surgery, these individuals developed greater beta-cell glucose sensitivity, and showed greater insulin and GLP-1 release early in the OGTT.

Entities:  

Keywords:  Beta-cell glucose sensitivity; GLP-1; Glucagon; Insulin sensitivity; Reactive hypoglycaemia; Roux-en-Y gastric bypass; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 30315341     DOI: 10.1007/s00125-018-4737-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  Increased risk of OGTT-induced hypoglycemia after gastric bypass in severely obese patients with normal glucose tolerance.

Authors:  Marie Pigeyre; Charlotte Vaurs; Violeta Raverdy; Hélène Hanaire; Patrick Ritz; François Pattou
Journal:  Surg Obes Relat Dis       Date:  2014-12-15       Impact factor: 4.734

2.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.

Authors:  Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-03-31       Impact factor: 91.245

3.  Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

Authors:  Marzieh Salehi; Amalia Gastaldelli; David A D'Alessio
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

4.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

5.  Hypoglycemia after gastric bypass: the dark side of GLP-1.

Authors:  Mary-Elizabeth Patti; Allison B Goldfine
Journal:  Gastroenterology       Date:  2014-01-24       Impact factor: 22.682

6.  How do we define cure of diabetes?

Authors:  John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

7.  PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.

Authors:  Anita M van den Hoek; Annemieke C Heijboer; Eleonora P M Corssmit; Peter J Voshol; Johannes A Romijn; Louis M Havekes; Hanno Pijl
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

8.  No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery.

Authors:  Carsten Dirksen; Aleksander Eiken; Kirstine N Bojsen-Møller; Maria S Svane; Christoffer Martinussen; Nils B Jørgensen; Jens J Holst; Sten Madsbad
Journal:  Obes Surg       Date:  2016-09       Impact factor: 4.129

9.  The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study.

Authors:  Dimitrios J Pournaras; Alan Osborne; Simon C Hawkins; David Mahon; Mohammad A Ghatei; Steve R Bloom; Richard Welbourn; Carel W le Roux
Journal:  Obes Surg       Date:  2009-10-14       Impact factor: 4.129

10.  Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion.

Authors:  Marzieh Salehi; Stephen C Woods; David A D'Alessio
Journal:  Obesity (Silver Spring)       Date:  2015-08-28       Impact factor: 5.002

View more
  6 in total

1.  Roux-en-Y gastric bypass surgery progressively alters radiologic measures of hypothalamic inflammation in obese patients.

Authors:  Mohammed K Hankir; Michael Rullmann; Florian Seyfried; Sven Preusser; Sindy Poppitz; Stefanie Heba; Konstantinos Gousias; Jana Hoyer; Tatjana Schütz; Arne Dietrich; Karsten Müller; Burkhard Pleger
Journal:  JCI Insight       Date:  2019-10-03

2.  Prevalence of hypoglycaemia in a random population after Roux-en-Y gastric bypass after a meal test.

Authors:  Marloes Emous; Merel van den Broek; Ragnhild B Wijma; Loek J M de Heide; Gertjan van Dijk; Anke Laskewitz; Erik Totté; Bruce H R Wolffenbuttel; André P van Beek
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 3.  Hypoglycemia After Upper Gastrointestinal Surgery: Clinical Approach to Assessment, Diagnosis, and Treatment.

Authors:  Amanda Sheehan; Mary Elizabeth Patti
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-19       Impact factor: 3.168

4.  Renal Sinus Fat Is Expanded in Patients with Obesity and/or Hypertension and Reduced by Bariatric Surgery Associated with Hypertension Remission.

Authors:  Emilia Moritz; Prince Dadson; Ekaterina Saukko; Miikka-Juhani Honka; Kalle Koskensalo; Kerttu Seppälä; Laura Pekkarinen; Diego Moriconi; Mika Helmiö; Paulina Salminen; Pirjo Nuutila; Eleni Rebelos
Journal:  Metabolites       Date:  2022-07-02

5.  Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass.

Authors:  Antonio Ferreira; Ahmed Fahiem Abdelsalam Emara; David Herzig; Andreas Melmer; Andreas P Vogt; Christos T Nakas; Andrea Facchinetti; Chiara Dalla Man; Lia Bally
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

6.  Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study.

Authors:  Kleopatra Alexiadou; Joyceline Cuenco; James Howard; Nicolai Jacob Wewer Albrechtsen; Ibiyemi Ilesanmi; Anna Kamocka; George Tharakan; Preeshila Behary; Paul R Bech; Ahmed R Ahmed; Sanjay Purkayastha; Robert Wheller; Matthieu Fleuret; Jens Juul Holst; Stephen R Bloom; Bernard Khoo; Tricia M-M Tan
Journal:  BMJ Open Diabetes Res Care       Date:  2020-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.